Clinical Trials on Refractory B Lymphoblastic Lymphoma

Total 5268 results

Kjeld Schmiegelow
Danish Child Cancer Foundation; Nordic Society for Pediatric Hematology and...

Completed

Thiopurine EnhAnced Maintenance Therapy (TEAM)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

Denmark
Beam Therapeutics Inc.

Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Lymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/Lymphoma

United States
University of Pennsylvania

Completed

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma

United States
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
National University Hospital, Singapore

Recruiting

Ma-Spore ALL 2020 Study

B Lymphoblastic Leukemia

Malaysia, Singapore
Hebei Senlang Biotechnology Inc., Ltd.

Unknown

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Recruiting

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

B-cell Acute Lymphoblastic Leukemia

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital

Active, not recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Relapsed B-Cell Acute Lymphoblastic Leukemia

United States
Wugen, Inc.

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

United States, Australia, Netherlands, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
Jazz Pharmaceuticals

Withdrawn

An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Spain
Nanfang Hospital of Southern Medical University

Recruiting

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Leukemia | Leukemia, B-cell | Leukemia, Acute | Leukemia, Lymphoblastic

China
Goethe University

Active, not recruiting

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
AIDS Malignancy Consortium
Center for International Blood and Marrow Transplant Research

Active, not recruiting

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (CS22-03)

HIV Infections | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Leukemia | Leukemia, Lymphoblastic | HIV Associated Lymphoma | HIV Disease; Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Withdrawn

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Molecular Templates, Inc.

Terminated

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma | Non-hodgkin Lymphoma,B Cell

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL)

Acute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic Leukemia

France
Abramson Cancer Center of the University of Pennsylvania

Completed

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Follicular Lymphomas | CD19+ Diffuse Large B-cell Lymphomas | Mantle Cell Lymphomas

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Leukemia, Lymphoblastic, Chronic

Italy
University of Washington
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Minimal Residual Disease | T Acute Lymphoblastic Leukemia

United States
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Seoul National University Hospital

Recruiting

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Relapsed/Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Not yet recruiting

A Phase I/II Study of Diffuse Large B-cell Lymphoma (DLBL)

Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc

Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States, Spain, Israel, Italy, Poland, China, Austria
Kite, A Gilead Company
Genentech, Inc.

Completed

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)

Refractory Diffuse Large B Cell Lymphoma

United States
Ruijin Hospital

Unknown

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Diffuse Large B-Cell Lymphoma Refractory

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Juventas Cell Therapy Ltd.

Not yet recruiting

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (B-ALL)

B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University

Recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell

China
Nantes University Hospital
Gilead Sciences; Institut Cancerologie de l'Ouest

Withdrawn

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia (EPRALLO)

Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
National Cancer Institute (NCI)

Terminated

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Therapeutic Advances in Childhood Leukemia Consortium

Recruiting

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Lymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCN

United States, Australia
Children's Mercy Hospital Kansas City
Millennium Pharmaceuticals, Inc.

Terminated

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
Bambino Gesù Hospital and Research Institute

Recruiting

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

B-cell Acute Lymphoblastic Leukemia

Italy
Amgen

Recruiting

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

B Cell Precursor Acute Lymphoblastic Leukemia

Japan, Australia, Spain, United States, Italy, Germany, France, Turkey, Canada, Netherlands, Austria
Amgen

Completed

Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)

B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Austria, Germany, Italy
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Jazz Pharmaceuticals

Approved for marketing

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma
BeiGene

Recruiting

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

Australia, Spain, United States, France, Hungary, New Zealand, Poland, Serbia, Canada, Romania
GWT-TUD GmbH
Hoffmann-La Roche

Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-cell Lymphoma

Germany, Spain, United Kingdom, Austria

Clinical Trials on Refractory B Lymphoblastic Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations